Concepedia

Azmi Nasser

AN

Statistics

Publications

24

Citations

840

H-Index

19

Active since

2013

Affiliations

Supernus Pharmaceuticals (United States)(Current)

SUNY Upstate Medical University

Reckitt Benckiser (United States)

Triangle

Virginia Commonwealth University

Azmi Nasser is an author at Supernus Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2013–2022

24

Publications

24

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2020 · 81 citations · Full text

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

Azmi Nasser, Mark K. Greenwald, Bradley Vince et al. · Journal of Clinical Psychopharmacology · 2015 · 74 citations · Full text

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Janet Johnson, Tesfaye Liranso, Keith E. Saylor et al. · Journal of Attention Disorders · 2019 · 60 citations · Full text

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2021 · 53 citations

, , +11

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi et al. · CNS Drugs · 2022 · 49 citations · Full text

1–5 of 24